NCT06618001View on ClinicalTrials.gov

A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

PHASE1RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

January 14, 2025

Primary Completion Date

July 15, 2027

Study Completion Date

August 15, 2028

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Neoplasms
Interventions
DRUG

JNJ-89853413

JNJ-89853413 will be administered.

Trial Locations (9)

28040

RECRUITING

Hosp Univ Fund Jimenez Diaz, Madrid

31008

RECRUITING

Clinica Univ. de Navarra, Pamplona

T2N 5G2

RECRUITING

Arthur J E Child Comprehensive Cancer Centre, Calgary

V5Z 1M9

RECRUITING

Vancouver General Hospital, Vancouver

M5G 2C1

RECRUITING

Princess Margaret Hospital, Toronto

08036

RECRUITING

Hosp Clinic de Barcelona, Barcelona

CB2 0QQ

RECRUITING

Addenbrookes Hospital, Cambridge

W1T 7HA

RECRUITING

University College London Hospitals, London

M20 4BX

RECRUITING

The Christie NHS Foundation Trust Christie Hospital, Manchester

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY